U.S. Markets closed

Oncotelic Therapeutics, Inc. (OTLC)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.2500-0.0050 (-1.96%)
At close: 3:52PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.2550
Open0.2550
BidN/A x N/A
AskN/A x N/A
Day's Range0.2482 - 0.2600
52 Week Range0.1600 - 0.3800
Volume117,063
Avg. Volume198,555
Market Cap23.23M
Beta (5Y Monthly)0.24
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.35
  • ONCOTELIC CLOSES COVID-19 CLINICAL TRIAL EARLY.
    GlobeNewswire

    ONCOTELIC CLOSES COVID-19 CLINICAL TRIAL EARLY.

    AGOURA HILLS, California, June 15, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) ("Oncotelic" or the “Company”), a leading developer of TGF-β therapeutics for oncology, infectious diseases and respiratory health announced that, as of June 11, 2021, Oncotelic has discontinued enrollment in its OT-101 clinical trial in patients with COVID-19. The trial completed randomization of 32 out of 36 patients planned, on an intent to treat basis. The total of 32 patients consisted of 2

  • Oncotelic Joins Chopra Foundation and Heart Foundation of India to Provide Relief for India's Explosive 2nd Wave of Covid.
    GlobeNewswire

    Oncotelic Joins Chopra Foundation and Heart Foundation of India to Provide Relief for India's Explosive 2nd Wave of Covid.

    AGOURA HILLS, California, May 04, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) ("Oncotelic"), a leading developer of TGF-β therapeutics for oncology and infectious disease and respiratory health will be working with Chopra Foundation and Heart Care Foundation to provide COVID-19 relief for India, including medicines and oxygen concentrators. Medicines will include PulmoHeal™, created by Oncotelic and our Indian partner - Windlas Biotech Pvt. Ltd. PulmoHeal™ is already available over-the-counter (OTC) in India on e-commerce platforms and pharmacies. PulmoHeal™ has been shown to improve long term respiratory recovery from COVID-19 and possibly from overuse of supplement oxygen- an area of unmet medical needs. The deployment of PulmoHeal™ on a large scale will also enable the use of its Post Marketing Survey platform (PMS), which includes the cough artificial intelligence (AI) platform. Put together, PulmoHeal™ will enable the collection of data on the progression of patients' response to COVID with its use, as well as other COVID medications. India is caught in a ferocious second wave of the coronavirus pandemic, with the Indian authorities reporting in excess of 400,000 new COVID-19 cases per day. Every one of these patients are participating in an uncontrolled clinical experimentation since there is no proven treatment protocol for COVID-19, except for dexamethasone. It is our objective to leverage our crowd source PMS platform to gather performance data across the multitude of experimental therapeutics being deployed on the Indian community such as Ivermectin, Vitamins, and Ayurvedic drugs. The goal is to arrive at definitive answer as to what is working and what is not working. “Heart Care Foundation of India has been involved in providing free oxygen concentrators to those patients whose oxygen levels are dropping and who are not able to find a bed or resource in hospitals. This humanitarian deployment of PulmoHeal™, together with oxygen, should be synergistic in both the immediate and long-term recovery of COVID-19 patients in India." Said Saran Saund, Chief Business Officer, Oncotelic. About the Chopra Foundation The Chopra Foundation is a 501 (c) (3) organization dedicated to improving health and well-being, cultivating spiritual knowledge, expanding consciousness, and promoting world peace to all members of the human family. The mission of the Chopra Foundation is to advance the cause of mind/body spiritual healing, education, and research through fundraising for selected projects. https://www.choprafoundation.org/ Chopra Foundation is using the Go Fund Me platform to raise donations which will be deployed to the non-profit Heart Care Foundation of India (HCFI) to donate supplies like oxygen tanks and concentrators as well as medicine therapies to citizens in need. For more information, please go to: https://gofund.me/7706fe54 About Heart Care Foundation: The Heart Care Foundation of India has been actively involved in literary activities as well as patient care since its inception and our efforts particularly gained pace during the Covid 19 pandemic as the need to educate and help more and more people was felt more than ever. Dr KK Aggarwal, President Heart Care Foundation of India, undertook a mission to educate more than 1% of the population on digital platforms. More than 30 million viewers have been sensitized on COVID in 2021 alone through various social media channels. The Heart Care Foundation is running a 12hr free OPD on Zoom, with the meeting ID - 84290921517. We have a team of covid educators and doctors offering free consultation to almost 1000 patients daily for free. Over 1000 school principals and teachers have been trained as COVID guides. The Heart Care Foundation also trained 1000 health educators in 2020. Regular update sessions are conducted on zoom to address the problems faced by patients daily as well by different experts. Heart Care Foundation of India has been involved in providing free oxygen concentrators to those patients whose oxygen levels are dropping and who are not able to find a bed or resource in hospitals. These oxygen concentrators are provided along with the treatment protocol which can be followed under the home management guidelines. The Heart Care Foundation is proud to announce this initiative saves- countless lives last year. This new wave of Covid 19 has been more deadly and dangerous and Heart Care Foundation of India has been on its toes to increase their resources to help the society at large About ARTIVeda™/PulmoHeal™ The product, ARTIVeda™ / PulmoHeal™ is a formulated plant extract of the indigenous plant Artemisia, known in Sanskrit texts as Damanaka. ARTIVeda™ / PulmoHeal™ is the first Ayurvedic drug against COVID-19 through TGF-β inhibition. ARTIVeda™ / PulmoHeal™ is expected to be effective through the entire infection cycle. The active component of ARTIVeda™ / PulmoHeal™ has been identified as artemisinin. Through proprietary GMP quality extraction and manufacturing processes, the Artemisia extract was rendered active against COVID-19 with robust Safety Index (SI) greater than 100 (ratio of nonspecific cell kill versus viral kill). Other extracts have SI <10. Testing was performed at the US NIAID core viral laboratory. ARTIVeda™ / PulmoHeal™ is protected by a patent portfolio of over 15 international patents by Oncotelic's R&D. The mechanism of action against COVID-19 has been confirmed in 5 key peer reviewed international scientific/medical publications. ARTIVeda™ / PulmoHeal™ is designed to target multiple viral threats including COVID-19 by suppressing both viral replication and clinical symptoms that arise from viral infection. We have a product to be a cost effective prophylactic suitable for global deployment. For more information please visit www.pulmoheal.com. About Oncotelic Oncotelic (formerly known as Mateon Therapeutics, Inc.) was created by the 2019 reverse merger with Oncotelic, which became a wholly owned subsidiary of Oncotelic, thereby creating an immuno-oncology company dedicated to the development of first in class RNA therapeutics as well as small molecule drugs against cancer and infectious diseases. OT-101, the lead immuno-oncology drug candidate of Oncotelic, is a first-in-class anti-TGF-βRNA therapeutic that exhibited single agent activity in some relapsed/refractory cancer patients in clinical trial settings. OT-101 also has shown activity against SARS-CoV-2 and COVID-19. Oncotelic is seeking to leverage its deep expertise in oncology drug development to improve treatment outcomes and survival of cancer patients with a special emphasis on rare pediatric cancers. Oncotelic has rare pediatric designation for DIPG (OT-101), melanoma (CA4P), and AML (OXi4503). For more information, please visit www.oncotelic.com and www.Oncotelic.com. Oncotelic's Cautionary Note on Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this communication regarding strategy, future operations, future financial position, prospects, plans and objectives of management are forward-looking statements. Words such as "may", "expect", "anticipate" "hope", "vision", "optimism", "design", "exciting", "promising", "will", "conviction", "estimate," "intend," "believe", "quest for a cure of cancer", "innovation-driven", "paradigm-shift", "high scientific merit", "impact potential" and similar expressions are intended to identify forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about future plans, the progress, timing, clinical development, scope and success of future clinical trials, the reporting of clinical data for the company's product candidates and the potential use of the company's product candidates to treat various cancer indications. Each of these forward-looking statements involves risks and uncertainties and actual results may differ materially from these forward-looking statements. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, failure of collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes. These risks are not exhaustive, the company faces known and unknown risks, including the risk factors described in the company's annual report on Form 10-K filed with the SEC on April 10, 2019 and in the company's other periodic filings. Forward-looking statements are based on expectations and assumptions as of the date of this press release. Except as required by law, the company does not assume any obligation to update forward-looking statements contained herein to reflect any change in expectations, whether as a result of new information future events, or otherwise. Contact Information:For Oncotelic Therapeutics, Inc.:Amit Shahashah@oncotelic.com

  • ONCOTELIC THERAPEUTICS, INC. ANNOUNCES POSITIVE TOP LINE DATA FOR ARTI-19 CLINICAL TRIAL EVALUATING PULMOHEAL™ VERSUS COVID-19.
    GlobeNewswire

    ONCOTELIC THERAPEUTICS, INC. ANNOUNCES POSITIVE TOP LINE DATA FOR ARTI-19 CLINICAL TRIAL EVALUATING PULMOHEAL™ VERSUS COVID-19.

    AGOURA HILLS, Calif., April 20, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB:OTLC), a leading developer of TGF-β therapeutics for oncology and COVID-19, reports positive top line data from its COVID-19 clinical trial, ARTI-19, evaluating PulmoHeal™ against COVID-19 in India. "We thank our investigators, patients, collaborators, and investors for their support in completion of ARTI-19, despite the challenging health environment in India, due to the recent surge in COVID-19 cases in India. Despite the challenges, we are working diligently to lock the dataset to complete our regulatory submission." said Dr. Vuong Trieu, CEO and Chairman of Oncotelic. PulmoHeal™ is being developed by Oncotelic, in partnership with Windlas Biotech Private Limited. We have shown that the active component of PulmoHeal™ is active against the influenza virus, which is consistent with the broad-spectrum activity for PulmoHeal™ and which is confirmed by its reported activity against multiple variants of SARS-CoV2: WT (USA/WA12020) SARS-CoV-2 and variants, B1.1.7 and B1.351. The top line data for ARTI-19 are as follow: No adverse events were reported that required discontinuation of treatment.PulmoHeal™, when added to the standard of care (SOC), accelerated the recovery of patients with mild to moderate COVID-19, across all COVID-19 symptoms examined.91% of WHO-4 pts achieved a reduction to WHO-3 on the first few doses of PulmoHeal™, p = 0.0037 (n= 56 / PulmoHeal + SOC vs n= 25 / SOC).All vitals were normalized by the end of the 28-day monitoring period.Most importantly, oxygen (O2) saturation fully recovered by day-28 with PulmoHeal™ + SOC (p=0.0003), but not with SOC alone (p=ns).The number of patients with O2 saturation < 95% reduced by 91% when treated with PulmoHealTM + SOC.In contrast, treatment with SOC alone only resulted in a 31% reduction.Similarly, respiratory rate fully recovered by day-28 with PulmoHeal™ + SOC (p<0.0001) but not with SOC alone (ns).SOC - Standard of Care included remdesivir, dexamethasone, heparin, ivermectin and others. "COVID-19 symptoms can sometimes persist for a long time due to substantial scarring of the targeted organs, including the lung. This aspect of COVID-19 therapy is very often neglected. Here we are seeing a full recovery of normal lung functions (O2 saturation and respiratory rate) when treated with PulmoHeal™." said Saran Saund, CBO and GM of AI Division, Oncotelic. About PulmoHeal™: PulmoHeal™ consists of three components: A mobile app called ArtiHealth™ powered by Oncotelic's AI platform that allows patients to submit a questionnaire and a daily cough recording to receive real-time information on their respiratory function and progress over time. Oncotelic has signed a joint development agreement with IBM Watson Health Research division to collectively work on AI models for respiratory assessments from Oncotelic's data collection initiatives.A post-marketing survey platform to crowd-source user experience for new indications.The drug PulmoHeal™, a broad-spectrum, lung therapy food supplement that is supported by a multi-center rigorous clinical study that has demonstrated efficacy against the viral respiratory infection- COVID-19; Additional information can be found at www.pulmoheal.com. About Oncotelic Therapeutics Oncotelic Therapeutics, Inc. (f/k/a Mateon Therapeutics, Inc.) ("Oncotelic"), was formed in the State of New York in 1988 as OXiGENE, Inc., was reincorporated in the State of Delaware in 1992, and changed its name to Mateon Therapeutics, Inc. in 2016, and Oncotelic Therapeutics, Inc. in November 2020. Oncotelic was created by the 2019 merger with Oncotelic Inc., which became a wholly owned subsidiary of Mateon, thereby creating an immuno-oncology company dedicated to the development of first in class RNA therapeutics, as well as small molecule drugs against cancer and infectious diseases. OT-101, the lead immuno-oncology drug candidate of Oncotelic, is a first-in-class anti-TGF-β RNA therapeutic that exhibited single agent activity in some relapsed/refractory cancer patients in clinical trial settings. OT-101 also has shown activity against SARS-CoV-2. Oncotelic is seeking to leverage its deep expertise in oncology drug development to improve treatment outcomes and survival of cancer patients with a special emphasis on rare pediatric cancers. Oncotelic also has rare pediatric designation for DIPG (OT-101), melanoma (CA4P), and AML (OXi 4503). The Company acquired PointR Data Inc. ("PointR") in November 2019. The PointR Acquisition was intended to create a publicly traded artificial intelligence driven immuno-oncology company with a robust pipeline of first in class TGF-β immunotherapies for late stage cancers such as gliomas, pancreatic cancer and melanoma. For more information, please visit www.oncotelic.com and www.mateon.com. Oncotelic's Cautionary Note on Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this communication regarding strategy, future operations, future financial position, prospects, plans and objectives of management are forward-looking statements. Words such as "may", "expect", "anticipate" "hope", "vision", "optimism", "design", "exciting", "promising", "will", "conviction", "estimate," "intend," "believe", "quest for a cure of cancer", "innovation-driven", "paradigm-shift", "high scientific merit", "impact potential" and similar expressions are intended to identify forward-looking statements. Forward looking statements contained in this press release include, but are not limited to, statements about future plans, the progress, timing, clinical development, scope and success of future clinical trials, the reporting of clinical data for the company's product candidates and the potential use of the company's product candidates to treat various cancer indications. Each of these forward-looking statements involves risks and uncertainties, and actual results may differ materially from these forward-looking statements. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, failure of collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes. These risks are not exhaustive, the company faces known and unknown risks, including the risk factors described in the Company's annual report on Form 10-K filed with the SEC on May 20, 2020 and in the company's other periodic filings. Forward-looking statements are based on expectations and assumptions as of the date of this press release. Except as required by law, the company does not assume any obligation to update forward-looking statements contained herein to reflect any change in expectations, whether as a result of new information future events, or otherwise. Contact Information:For Oncotelic Therapeutics, Inc.:Amit Shahashah@oncotelic.com